{"id":"dna-intercalators","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL3037898","moleculeType":"Unknown","molecularWeight":"1025.71"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"DNA intercalators are planar aromatic compounds that wedge between the double helix strands of DNA, distorting the helical structure and blocking DNA synthesis and RNA transcription. This mechanism is particularly effective against rapidly dividing cancer cells that depend on active DNA replication. The class includes both classical agents (e.g., doxorubicin, daunorubicin) and newer investigational compounds being evaluated in phase 2 trials.","oneSentence":"DNA intercalators insert themselves between DNA base pairs to disrupt DNA replication and transcription, leading to cancer cell death.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:33:41.772Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various solid tumors and hematologic malignancies (specific indications under phase 2 evaluation by UNICANCER)"}]},"trialDetails":[{"nctId":"NCT04870437","phase":"NA","title":"Impact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation.","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2022-04-27","conditions":"Kidney Transplantation","enrollment":30},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT00060671","phase":"PHASE3","title":"Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"CTI BioPharma","startDate":"2005-01","conditions":"Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular","enrollment":800},{"nctId":"NCT00060684","phase":"PHASE1","title":"Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2001-12","conditions":"Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic, Lymphoma, Mixed-Cell, Follicular","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":427,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["capecitabine","5-FU","gemcitabine"],"phase":"phase_2","status":"active","brandName":"DNA intercalators","genericName":"DNA intercalators","companyName":"UNICANCER","companyId":"unicancer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DNA intercalators insert themselves between DNA base pairs to disrupt DNA replication and transcription, leading to cancer cell death. Used for Various solid tumors and hematologic malignancies (specific indications under phase 2 evaluation by UNICANCER).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}